Crossref
Selective Anticancer Effects by Oxyclozanide in Triple-Negative Breast Cancer Expressing S100A9
Drug Targets and Therapeutics · 2022
DOI: 10.58502/dtt.22.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Targets and Therapeutics, 2022. Verfasst von Hyun Hwan Hwang und 11 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hwang, H. H., Chang, K. H., Choi, Y. Y., Jung, I., Kang, I., Choi, Y., O, M. J., Cho, C., Kang, P., Park, H., Jang, C., & Lee, S. (2022). Selective Anticancer Effects by Oxyclozanide in Triple-Negative Breast Cancer Expressing S100A9. Drug Targets and Therapeutics. https://doi.org/10.58502/dtt.22.003
Vancouver
Hwang HH, Chang KH, Choi YY, Jung I, Kang I, Choi Y, et al. Selective Anticancer Effects by Oxyclozanide in Triple-Negative Breast Cancer Expressing S100A9. Drug Targets and Therapeutics. 2022. doi:10.58502/dtt.22.003
BibTeX
@article{Hwang2022,
author = {Hwang, Hyun Hwan and Chang, Ki Ho and Choi, Yi Young and Jung, Ii-Du and Kang, In-Cheol and Choi, Youngjin and O, Mi Jin and Cho, Chang-Keun and Kang, Pureum and Park, Hye-Jung and Jang, Choon-Gon and Lee, Seok-Yong},
title = {Selective Anticancer Effects by Oxyclozanide in Triple-Negative Breast Cancer Expressing S100A9},
journal = {Drug Targets and Therapeutics},
year = {2022},
doi = {10.58502/dtt.22.003}
}
EUVIMED